Empagliflozin safe in acute HF, improves 'Clinical Benefit' over time

Published On 2021-12-02 05:12 GMT | Update On 2021-12-15 06:31 GMT

Patients with acute heart failure were safely started on empagliflozin a median of 3 days after hospitalization and were 36% more likely to "experience a clinical benefit" over the next 90 days compared with patients taking a placebo, the EMPULSE trial highlights.

The benefits of empagliflozin in this very early acute setting, included better survival, fewer hospitalizations, and greater improvements quality of life (QoL)—all of which made up the primary composite endpoint in this study

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Empagliflozin safe in acute HF, improves 'Clinical Benefit' over time

Similar News

Long Term Arsenic Exposure May Be Risk Factor for Cardiovascular Disease: Study Reveals

Schizophrenia Linked to Fourfold Increase in Sudden Cardiac Death Risk: Study Finds

SOUL Trial Shows 14% Reduction in Cardiovascular Events with Oral Semaglutide in Type 2 Diabetes

ASA New Guidelines: Screening and Lifestyle Changes May Prevent First Stroke

'Strawberries' Natural and Delicious Way to Support Heart Health: Study Suggests

Folic Acid and Vitamin B12 Deficiencies Tied to Higher Blood Pressure in Children, Study Reveals

Study Unveils Connection Between Snoring and Elevated Blood Pressure

Exposure to Common Consumer Product Chemicals May Be Linked to Cardiac Electrical Changes, Study Reveals